Clinical Trials

Vir's Hepatitis Delta Combo Hits Every Phase 3 Target: 79% Undetectable

2026-11-08

Vir Biotechnology (Nasdaq: VIR) said Sunday that its monthly hepatitis delta combination of elebsiran and tobevibart met every endpoint in the pivotal Phase 3 ECLIPSE 1 trial — 79% of treated patie...